Company Overview and News

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

15h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

15h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

16h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

16h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRICING SUPPLEMENT (Prospectus)

18h sec.gov
June 20, 2018 Registration Statement Nos. 333-222672 and 333-222672-01; Rule424(b)(2)
JPM

16
JPM / JPMorgan Chase & Co. PRICING SUPPLEMENT (Prospectus)

18h sec.gov
June 20, 2018 Registration Statement Nos. 333-222672 and 333-222672-01; Rule424(b)(2)
JPM

139
Buffett, Bezos and Dimon Found Their CEO -- Now Comes the Hard Part | InvestorPlace

18h investorplace
If you’re a medical practitioner being asked by Jeff Bezos, Warren Buffett and Jamie Dimon to head up a potentially historical healthcare initiative that conveniently doesn’t have to worry about making money has got to feel like winning the Powerball lottery.
BRK.A AMZN JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

19h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

19h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

19h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRELIMINARY PRICING SUPPLEMENT (Prospectus)

19h sec.gov
The information in this preliminary pricing supplement is not complete and may be changed. This preliminary pricing supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. Subject to completion dated June 22, 2018
JPM

16
JPM / JPMorgan Chase & Co. PRICING SUPPLEMENT (Prospectus)

20h sec.gov
June 20, 2018 Registration Statement Nos. 333-222672 and 333-222672-01; Rule 424(b)(2)
JPM

16
JPM / JPMorgan Chase & Co. PRICING SUPPLEMENT (Prospectus)

20h sec.gov
June 20, 2018 Registration Statement Nos. 333-222672 and 333-222672-01; Rule 424(b)(2)
JPM

16
JPM / JPMorgan Chase & Co. PRICING SUPPLEMENT (Prospectus)

20h sec.gov
June 20, 2018 Registration Statement Nos. 333-222672 and 333-222672-01; Rule424(b)(2)
JPM

16
JPM / JPMorgan Chase & Co. PRICING SUPPLEMENT (Prospectus)

20h sec.gov
June 20, 2018 Registration Statement Nos. 333-222672 and 333-222672-01; Rule424(b)(2)
JPM

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to JPM / JPMorgan Chase & Co. on message board site Silicon Investor.

J.P. Morgan Chase (JPM) J P Morgan Chase
JP Morgan Chase u0026 Co. I THINK THIS IS ABSOLUTELY PRISTINE
DONKEY-FREE ZONE... sorry, no donkeys allowed Paint The Sky
Paint The Barstool JP Morgan/Bank of America/ High Flyers
J.P. Morgan u0026 Co. Inc. (NYSE:JPM) JPMX
CUSIP: 46625H100